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Abstract
OBjECTIVE: To observe the efficacy and safety of
oral Sanhuangwuji powder, anti-rheumatic drugs
(ARDs), and ginger-partitioned acupoint stimula-
tion at Zusanli (ST 36) on the treatment of rheuma-
toid arthritis (RA) complicated by peptic ulcer.
METHODS: This prospective randomized con-
trolled study included 180 eligible inpatients and
outpatients randomly assigned to an ARD treat-
ment (n = 60), ginger-partitioned stimulation (n =
60), or combination treatment (n = 60). Patients as-
signed to the ARD group were given oral celecoxib,
methotrexate, and esomeprazole. Patients as-
signed to theginger-partitioned stimulation group
were given ginger-partitioned acupoint stimula-
tion at Zusanli (ST 36) in addition to the ARDs. Pa-
tients in the combination treatment group were
given oral Sanhuangwuji powder,ginger-parti-
tioned acupoint stimulation at Zusanli (ST 36), and
ARDs. All patients were followed up for 2 months to
evaluate clinical effects and safety. The study was
registered in the World Health Organization data-
base at the General Hospital of Chengdu Military
Area Command Chinese People's Liberation Army
(ChiCTR- TCC12002824).
RESULTS: The combination treatment group had
significantly greater improvements in RA symp-
toms, laboratory outcomes, and gastrointestinal
symptom scores, compared with the other groups
(P < 0.05). The peptic ulcer healing rate in the com-
bination treatment group was significantly greater
than that in the ARD treatment group (χ2 = 16.875,
P < 0.05) and the ginger-partitioned stimulation
group (χ2 = 6.171, P < 0.05).
CONCLUSION: Combination treatment with gin-
ger-partitioned acupoint stimulation at Zusanli (ST
36), oral Sanhuangwuji powder, and ARDs had a
better clinical effect for RA with complicated peptic
ulcer, compared with ARD treatmentalone or in
combination with ginger-partitioned acupoint
stimulation.
© 2015 JTCM. All rights reserved.
Key words: Arthritis, rheumatoid; Peptic ulcer;
Point ST 36 (Zusanli); Sanhuangwuji powder; Ran-
domized controlled trial
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INTRODUCTION
Rheumatoid arthritis (RA) is a common autoimmune
disorder with a worldwide incidence of 1%-2% .1 Ac-
tive RA manifests primarily as synovitis of small joints,
which causes joint swelling and pain.1 Non-selective
non-steroidal anti-inflammatory drugs (NSAIDs) are
frequently prescribed to alleviate arthralgia and control
synovitis. However, these drugs can have serious ad-
verse effects, especially on the gastrointestinal (GI)
tract, and are likely to induce peptic ulcers. Thomas et
al 2 used endoscopy to follow up patients with RA who
were medicated with non-selective NSAIDs for 3 con-
secutive months, and found that approximately 25%
of patients suffered from peptic ulcers, with a three-fold
increase in morbidity rate.3 Matsukawa et al 4 reported
that the incidence of gastric ulceration was 80.6% in
patients with RA medicated with aspirin. The adverse
effects of non-selective NSAIDs are believed to be asso-
ciated with cyclooxygenase (COX)-1 inhibition. There-
fore, NSAIDs that selectively inhibit COX-2 (coxibs)
have been developed, and are effective for alleviating sy-
novitis with minimal adverse GI effects. Nevertheless,
Raymond et al 5 reported that the frequency of GI inju-
ry, erosion, or ulceration was 21.4% after 12 weeks in
RA patients given celecoxib, a COX-2 inhibitor.
Recently published studies have focused on the prophy-
laxis of NSAID-induced ulcers. Combination treat-
ment with a proton pump inhibitor and an NSAID sig-
nificantly decreases the risk of peptic ulceration in pa-
tients with RA.6 Höer et al 7 found that concomitant
prescription of a proton pump inhibitor with diclofe-
nac reduced the odds ratios of ulcer-associated hospital-
ization from 2.4 to 1.3. Wayne et al 8 suggested that
co-administration of a proton pump inhibitor with an
NSAID was as effective as a coxib at reducing
NSAID-induced gastropathy risk. Similarly, García-Ro-
dríguez et al 9reported that coxibs conferred a lower risk
of serious upper GI complications than NSAIDs, and
the addition of gastroprotective co-therapy reduced the
NSAID-associated risk by nearly 40% . Chan et al 10
noted that patients taking celecoxib with esomepra-
zole, but not low-dose aspirin, had a lower risk of re-
current peptic ulcer bleeding than patients treated with
celecoxib alone.
The treatment of RA complicated by peptic ulcer is
challenging, and no standardized protocol exists in clin-
ical practice. A conventional RA treatment regimen
will not be effective in this scenario because the use of
NSAIDs, including COX-2 inhibitors, or corticoste-
roids is limited in patients with gastric ulcers or con-
comitant gastric and duodenal ulcers.
Moxibustion is an important technique within Tradi-
tional Chinese Medicine, and stimulating the Zusanli
(ST 36) acupoint has been shown to be effective for
treating RA. We aimed to investigate the clinical effect
and safety of oral Sanhuangwuji powder, used in com-
bination withZusanli (ST 36) acupoint stimulation an-
danti-rheumatic drugs for the treatment of active RA
complicated by peptic ulcer.
MATERIALS ANDMETHODS
Patients
Patients aged 45-65 years with RA and peptic ulcer dis-
ease were included in the trial. Sample size was deter-
mined according to the clinical test 1∶1 control, 20%
surplus principle, and parallel design number estima-
tion table. Two hundred patients were initially enrolled.
Ten patients did not meet the inclusion criteria for af-
ter further screening, and six patients declined to par-
ticipate, still four patients who had other reasons were
excluded. In total, 180 inpatients or outpatients with
RA and complicated peptic ulcer were prospectively
and consecutively enrolled at the Traditional and West-
ern Medicine Department of Rheumatology, PLA
Chengdu General Hospital China between July 2008
and July 2013. Patients were equally and randomly as-
signed to three treatment groupsby random number ta-
ble (Figure 1). The study wasregistered in the World
Health Organization database at the General Hospital
of Chengdu Military Area Command Chinese People's
Liberation Army (ChiCTR-TCC12002824), and was
approved by the hospital's ethics committee and insti-
tutional review board. All participants gave a written
informed consent before inclusion.
Diagnosis and syndrome differentiation of RA
RA was diagnosed in accordance with the revised crite-
ria for RA classification established by the American
Rheumatism Association in 1987.11 Active disease was
defined as an aggravated joint swelling and pain, in-
creased erythrocyte sedimentation rate (ESR), and ele-
vated C-reactive protein (CRP). Traditional Chinese
Medicine (TCM) syndrome differentiation of RA was
performed in accordance with the Guidelines for Clini-
cal Study of Traditional Chinese Medicine New
Drugs.12
Inclusion criteria
Patients were included if they had: active RA and a
TCM syndrome differentiation of arthralgia (aggravat-
ed arthralgia with a concomitant syndrome of damp-
ness and heat blocking collaterals); were aged 45-65
years; and had a diagnosis of complicated peptic ulcer
confirmed by endoscopy. Patients must not have had
previous treatment for RA and peptic ulcer using TCM
or Western drugs. Patients must give written and in-
formed consent before enrollment.
Exclusion criteria
Patients were excluded from this study if they had: al-
lergies to any test medications; complicated Helico-
bacter pylori infection, GI cancer, or GI bleeding; any
other autoimmune disorders; serious concomitant car-
diac, cerebral, hepatic, renal, hematological, or endo-
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crine disorders; or impaired consciousness or psychiat-
ric disorders. Patients were also excluded if they partici-
pated in any other clinical studies within the previous
3 months, or for any other reasons at the discretion of
the investigators. Pregnant or lactating women were al-
so excluded.
Treatments
ARD treatment. Patients were given 20-mg oral esome-
prazole magnesium enteric-coated tablets (Astra Zene-
ca, London, UK) once daily, 5 min before breakfast;
100-mg oral celecoxib capsules (Pfizer, New York, NY,
USA) twice daily; and 15-mg oral methotrexate tablets
(Sine Pharmaceutical Co., Ltd., Shanghai, China) once
weekly.
Ginger-partitioned stimulationof the Zusanli (ST 36)
acupoint. Patients were administered ARD treatment
and ginger-partitioned stimulation at Zusanli (ST 36).
A 5-mm-thick fresh ginger slice was placed over Zusan-
li (ST 36) and the point was stimulated with the endur-
able heat from a burning moxa-stick for 10-15 min.
Moxibustion was performed twice daily.
Combination treatment. Patients were administered
ARD treatment, moxibustion, and oral Sanhuangwuji
powder (10 g per dose, three times a day). Sanhuang-
wuji powder was prepared by PLA Chengdu General
Hospital Pharmacy, and contained Huangqin (Radix
Scutellariae Baicalensis) 15 g, Huanglian (Rhizoma Cop-
tidis) 10 g, Huangbai (Cortex Phellodendri Amurensis)
15 g, Dilong (Pheretima Aspergillum) 10 g, Haipiaoxi-
ao (Endoconcha Sepiellae) 30 g, and Baiji (Rhizoma
Bletillae Striatae) 15 g. This powder was taken alone,
and the patients were instructed to avoid any raw,
cold, spicy, or tough foods, and alcohol during the
treatment. One treatment cycle lasted 4 weeks, and a
follow-up fiber-optic endoscopy was repeated after two
cycles of treatment.
Outcome measures
Outcome measures included the number of swollen
joints, the number of tender joints, the duration of
morning stiffness, gripping strength, self-reported pain
score, DAS-28 RA disease activity score, a health assess-
ment questionnaire (HAQ) for quality of life, levels of
serum rheumatoid factor (RF), anti-cyclic citrullinated
peptide (anti-CCP), ESR, and CRP. These were assessed
at the baseline, and 4 and 8 weeks after treatment. Any
GI symptoms, such as abdominal pain, reflux, belch-
ing, and abdominal distension, were documented and
semi-quantitatively scored. A GI endoscopy was per-
formed at baseline and 8 weeks after treatment.
Evaluation of RA treatment efficacy
RA treatment efficacy outcomes were classified based
on ACR20, ACR50, and ACR70 improvement crite-
ria, as established by the American College of Rheuma-
tology.13 Briefly, ACR20 refers to a 20% improvement
in the number of tender and swollen joints and more
than a 50% reduction in scores for at least three items
out of: the pain visual analog scale (VAS), the pa-
tient-reported symptom score, the physician-reported
symptom score, the HAQ, and RF, ESR, or CRP lev-
els. ACR50 and ACR70 respectively refer to 50% and
70% improvements in the same metrics as ACR20. RA
treatment outcome was determined to be significantly
effective if ACR70 was achieved (primary symptoms,
Assessed for eligibility
(n = 200)
Excluded (n=20)
Notmeeting inclusion criteria (n = 10)
Declined to participate (n = 6)
Other reasons (n = 4)
Randomized groups
(n = 3)
Allocated to combination
treatment group (n = 60)
Received allocated
intervention (n = 20)
Allocated to ARD treatment
group (n = 60)
Received allocated
intervention (n = 20)
Allocated tomoxibustion
treatment group (n = 60)
Received allocated
intervention (n = 20)
Lost to follow-up (n = 0)
Discontinued intervention
(n = 0)
Lost to follow-up (n = 0)
Discontinued intervention
(n = 0)
Lost to follow-up (n = 0)
Discontinued intervention
(n = 0)
Analyzed (n = 60)
Excluded from analysis
(n = 0)
Analyzed (n = 60)
Excluded fromanalysis
(n = 0)
Analyzed (n = 60)
Excluded from analysis(n = 0)
Figure1 Flow chart of participation in this study
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signs, RF, ESR, and CRP improved, with an overall im-
provement in the score of > 70%); moderately effective
if ACR50 was achieved (primary symptoms, signs, RF,
ESR and CRP improved, with an overall improvement
in the score of 20%-70%); or ineffective if ACR20 was
not achieved (primary symptoms, signs, RF, ESR and
CRP improved, with an overall improvement in the
score of < 20%). The primary symptoms and signs in-
cluded the number of swollen joints, the number of
tender joints, the duration of morning stiffness, the av-
erage gripping strength, and the pain VAS. The im-
provement rate was defined as the mean of the im-
provement percentages [(pre-treatment score −
post-treatment score)/pre-treatment score × 100%] for
the five outcome measures.
Evaluation of peptic ulcer treatment effect
All patients were followed up at 4 weeks and 8 weeks
to assess the GI symptom score and the clinical efficacy
of peptic ulcer treatment.14 Peptic ulcer treatment out-
come was determined to be ineffective if the reduction
in ulcer area was < 50%, with aggravation of abdomi-
nal pain and symptoms of abdominal irritability; mod-
erately effective if the reduction in ulcer area was >
50% , with the disappearance of abdominal pain and
symptoms of abdominal irritability; or significantly ef-
fective if the ulcer, abdominal pain, and symptoms of
abdominal irritability disappeared, with all laboratory
parameters returning to normal. The overall rate of treat-
ment success was defined as the percentage of patients
exhibiting moderately or significantly effective treat-
ment outcomes. The GI symptom score was semi-
quantitatively graded as follows: 0 points, no GI symp-
toms; 1 point, mild symptoms requiring no medication;
2 points, moderate symptoms with slight impairment
in daily life; and 3 points, severe symptoms requiring
medication, with serious impairment in daily life.
Evaluation of endoscopic peptic ulcer treatment effi-
cacy
The efficacy of peptic ulcer treatmentby endoscopy
was assessed as previously described.15 Peptic ulcer treat-
ment outcome was determined to be: clinically cured if
the ulcer completely disappeared, and there was no ob-
vious edema; significantly effective if the ulcer disap-
peared, but there was still obvious inflammation; mod-
erately effective if the reduction in ulcer area was >
50%; or ineffective if the reduction in ulcer area was <
50%.
Statistical analysis
SPSS 12.0 (SPSS Inc., Chicago, IL, USA) was used for
statistical analysis. All continuous data are expressed as
the mean ± standard deviation ( xˉ ± s), and were com-
pared using analysis of variance followed by the least
significant difference test. All categorical data were
compared using a multiple, independent samples
non-parametric test. A P-value < 0.05 was considered
statistically significant.
RESULTS
Patient characteristics
The combination treatment group (n = 60) included
14 men and 46 women with a mean age of (56 ± 6)
years (range 45-65 years), and a mean RA history of
(9 ± 5) years (range 2-20 years). The ARD treatment
group (n = 60) included 12 men and 48 women
aged (56 ±6) years (range 45-65 years), and a mean
RA history of (9 ± 6) years (range 1.5-21 years). The
ginger-partitioned stimulation group (n = 60) includ-
ed 13 men and 47 women aged (56 ± 6) years
(range 45-65 years), with a mean RA history of (9 ±
6) years (range 2.5-22 years). The three groups were
comparable in terms of sex, age, and history of RA
(P > 0.05).
Clinical efficacy of RA treatment
The clinical efficacy outcomes for the treatment of RA
are shown in Table 1. At baseline, all groups were com-
parable in terms of the number of swollen joints, num-
ber of tender joints, duration of morning stiffness, pain
VAS, HAQ score, and DAS-28 score (P > 0.05). Com-
pared with the baseline measurements, significant im-
provements in the primary symptoms and signs were
observed in all groups 4 and 8 weeks after treatment
(P < 0.05). The combination treatment group had a
significantly greater improvement, compared with the
ARD group (P < 0.05) and the ginger-partitioned stim-
ulation group (P < 0.05).
Laboratory efficacy of RA treatment
The laboratory efficacy outcomes for RA treatment
are shown in Table 2. At baseline, all groups were
comparable with regard to platelet count, ESR, se-
rum CRP level, serum RF level, and anti-CCP titer
(P > 0.05). Compared with baseline values, laborato-
ry parameters improved significantly in the combina-
tion treatment group 4 and 8 weeks after treatment
(P < 0.05). Fourweeks after treatment, the ARD
treatment group exhibited significant improvements
in platelet count, ESR, and serum CRP level (P <
0.05), but no significant changes in serum RF level
or anti-CCP titer (P > 0.05). Four weeks after treat-
ment, there was a significant improvement in platelet
count, ESR, serum CRP level, and serum RF level in
the ginger-partitioned stimulation group (P < 0.05),
but no significant alteration in the anti-CCP titer (P >
0.05) compared with the baseline. These three treat-
ment groups showed significant improvements in plate-
let count, ESR, serum CRP level, serum RF level, and
anti-CCP titer 8 weeks after treatment (P < 0.05), rela-
tive to the baseline. Eight weeks after treatment, the
combination treatment group had a significantly great-
er improvement in all parameters compared with the
ARD treatment group (P < 0.05).
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GI symptoms
GI symptom scores are shown in Table 3. At baseline,
the three groups were comparable in terms of GI symp-
tom score (P > 0.05). Compared with the baseline val-
ue, the GI symptom score in the combination treat-
ment group was significantly higher 4 and 8 weeks af-
ter treatment (P < 0.05). Compared with the baseline,
the ARD treatment group exhibited no significant im-
provement (P > 0.05) in GI symptom scores 4 weeks
after treatment, while the ginger-partitioned stimula-
tion group had a significant improvement 4 and 8
weeks after treatment (P < 0.05). The combination
treatment group had a significantly greater improve-
ment than that of the ARD treatment and ginger-parti-
tioned stimulation groups 8 weeks after treatment (P <
0.05).
Clinical efficacy of peptic ulcer treatment
The clinical outcomes for the treatment of peptic ulcer
are shown in Table 4. The overall success rate was
95% in the combination treatment group after two cy-
cles of treatment. This rate was significantly higher
than that in the ARD treatment group (χ2 = 16.875,
P < 0.05), and the ginger-partitioned stimulation
group (χ2 = 6.171, P < 0.05).
Efficacy of endoscopic peptic ulcer treatment
The effect outcomes of endoscopic peptic ulcer are
shown in Table 5. The overall success rate was 96.7%
in the combination treatment group after two cycles of
treatment. This rate was significantly higher than that
in the ARD treatment group (χ2 = 16.875, P < 0.05),
and the ginger-partitioned stimulation treatment
group (χ2 = 6.171, P < 0.05).
Group
Combination
treatment
ARD
treatment
Moxibustion
treatment
n
60
60
60
Time point
(week)
0
4
8
0
4
8
0
4
8
Number of
swollen joints
13.9±4.6
4.9±1.3ab
1.9±1.2ab
13.8±4.5
7.1±2.6a
4.8±0.7a
13.8±4.7
5.5±1.6a
2.7±1.0a
Number of
tender joints
16.2±4.3
9.0±2.7a
3.2±1.9ab
16.0±4.5
10.1±3.1a
6.6±1.3a
16.1±4.4
8.3±2.1a
4.8±1.3a
Duration of morning
stiffness (min)
196.7±45.8
124.3±20.6a
53.3±27.9ab
197.3±51.1
146.7±30.4a
89.8±26.6a
196.9±47.9
136.7±27.7a
67.8±23.7a
Pain VAS
7.9±1.3
3.4±1.1ab
1.5±0.8ab
7.8±1.2
5.2±1.3a
3.5±1.2a
7.9±1.4
4.0±1.5a
2.3±1.3a
HAQ
17.8±2.7
8.4±1.8ab
3.3±1.5ab
17.6±2.9
11.5±2.3a
6.6±1.7a
17.7±3.1
8.0±1.9a
4.6±1.7a
DAS-28
7.3±1.4
3.2±1.2ab
1.3±0.6ab
7.0±1.5
5.6±1.7a
3.7±1.1a
7.2±1.6
4.3± .5a
2.5±0.9a
Table 1 RA-associated symptoms and signs ( xˉ ± s)
Notes: ARD treatment group: patients were treated with 20-mg oral esomeprazole magnesium enteric-coated tablets once daily, 100-mg
oral celecoxib capsules twice daily,and 15-mg oral methotrexate tablets once weekly. Moxibustiontreatment group: patients were adminis-
tered ARD treatment plus ginger-partitioned moxibustion at Zusanli (ST 36). Combination treatment group: patients were administered
ARD treatment, moxibustion, and oral Sanhuangwuji powder (10 g per dose, three times a day). All treatments lasted 8 weeks. ARD: an-
ti-rheumatic drug; VAS: visual analog scale; HAQ: health assessment questionnaire; DAS: disease activity score. aP < 0.05 for intragroup
comparison; bP < 0.05 for intergroup comparison.
Group
Combination treatment
ARD treatment
Moxibustion treatment
n
60
60
60
Time point
(week)
0
4
8
0
4
8
0
4
8
Platelets
(10^9/L)
389±71
305±58ab
188±70 ab
379±71
346±61
276±62a
379±71
320±46a
256±72a
ESR
(mm/h)
99±29
41±17 ab
22±12 ab
97±29
66±28a
42±26a
97±29
61±24a
34±16a
CRP9
(mg/L)
78±41
23±18 ab
11±7 ab
74±41
48±21a
28±12a
74±41
35±20a
20±14a
RF
(IU/mL)
576±421
320±286 ab
179±101 ab
571±412
526±388
325±200a
571±412
477±264a
308±180a
Anti-CCP
(RU/mL)
285±178
132±139 ab
78±43 ab
280±180
221±141
106±70a
280±180
201±121
98±42a
Table 2 RA-associated laboratory parameters ( xˉ ± s)
Notes: ARD treatment group: patients were given 20-mg oral esomeprazole magnesium enteric-coated tablets once daily, 100-mg oral cele-
coxib capsulestwice daily, and 15-mg oral methotrexate tablets once weekly. Moxibustion treatment group: patients were administered
ARD treatment plus ginger-partitioned moxibustion at Zusanli (ST 36). Combination treatment group: patients were administered ARD
treatment, moxibustion, and oral Sanhuangwuji powder (10 g per dose, three times a day). All treatments lasted 8 weeks. ARD: anti-rheu-
matic drug; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; RF: rheumatoid factor. aP < 0.05 for intragroup comparison;
bP < 0.05 for intergroup comparison.
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DISCUSSION
In TCM, RA is classified as arthralgia or gout, and mani-
fests primarily as joint swelling, burning sensations,
and pain. RA is also normally diagnosed asaccumulat-
ed dampness-heat. A dampness-heat disorder is
thought to result from chronic refractory Yin-Yang dis-
harmony and dampness-heat crosslinking, which leads
to joint swelling, burning pain, numbness, and paralysis.
Moxibustion is a TCM modality often used for prophy-
laxis and treatment. The technique acts directly on the
disease site, which promotes analgesic and anti-inflam-
matory effects. Moxibustion is cheap, easy to use, and
has few adverse effects. Zusanli (ST 36), an acupoint
on the stomach channel, is preferred for the treatment
of GI disorders in accordance with combination treat-
ment theory for visceral disorders. Stimulating Zusanli
(ST 36) is believed to invigorate the spleen and stom-
ach, and regulate Qi flow for pain relief. Warming acu-
puncture can bidirectionally regulate disease via the
meridians,15 and warming acupuncture at the Zusanli
(ST 36) acupoint has been reported to reduce aspi-
rin-induced adverse GI effects.16 The combination of
warming acupuncture and ARD was shown to improve
RA treatment efficacy and minimize the adverse effects
of NSAIDs.17 Li et al 18,19reported that partitioned moxi-
bustion combined with methotrexate suppressed serum
interleukin (IL)-1β, tumor necrosis factor (TNF)-α,
Group
Combination treatment
ARD treatment
Moxibustion treatment
n
60
60
60
Significantly effective
48 (80)
36 (60)
42 (70)
Moderately effective
9 (15)
3 (5)
6 (10)
Ineffective
3 (5)
21 (35)
12 (20)
Overall success
19 (95)
13 (65)
16 (80)
Notes: ARD treatment group: patients were given 20-mg oral esomeprazole magnesium enteric-coated tablets once daily, 100-mg oral cele-
coxib capsules twice daily, and 15-mg oral methotrexate tablets once weekly. Moxibustion treatment group: patients were administered
ARD treatment plus ginger-partitioned moxibustion at Zusanli (ST 36). Combination treatment group: patients were administered ARD
treatment, moxibustion, and oral Sanhuangwuji powder (10 g per dose, three times a day). All treatments lasted 8 weeks. ARD: anti-rheu-
matic drug.
Table 4 Clinical efficacy outcomes for peptic ulcer [(n)%]
Notes: ARD treatment group: patients were given 20-mg oral esomeprazole magnesium enteric-coated tablets once daily, 100-mg oral cele-
coxib capsules twice daily, and 15-mg oral methotrexate tablets once weekly. Moxibustion treatment group: patients were administered
ARD treatment plus ginger-partitioned moxibustion at Zusanli (ST 36). Combination treatment group: patients were administered ARD
treatment, moxibustion, and oral Sanhuangwuji powder (10 g per dose, three times a day). All treatments lasted 8 weeks. ARD: anti-rheu-
matic drug.
Group
Combination treatment
ARD treatment
Moxibustion treatment
n
60
60
60
Clinical cure
44 (73.3)
24 (40)
30 (50)
Significantly effective
10 (16.7)
6 (10)
7 (11.7)
Moderately effective
4 (6.7)
10 (16.7)
11 (18.3)
ineffective
2 (3.3)
20 (33.3)
12 (20)
Overall success
96.7
66.7
80.0
Table 5 Endoscopic efficacy outcomes for peptic ulcer [(n)%]
Group
Combination treatment
ARD treatment
Moxibustion treatment
n
60
60
60
Time point (week)
0
4
8
0
4
8
0
4
8
Abdominal pain
2.1±0.6
1.1±0.7ab
0.3±0.4ab
2.1±0.6
1.7±0.5
0.7±0.5a
2.1±0.6
1.4±0.6a
0.5±0.5a
Reflux
2.3±0.5
1.1±0.6ab
0.4±0.5ab
2.3±0.6
1.9±0.4
0.9±0.8a
2.3±0.6
1.6±0.4a
0.6±0.4a
Belching
2.1±0.4
1.0±0.6ab
0.5±0.5ab
2.1±0.4
1.8±0.6
1.0±0.6a
2.1±0.4
1.4±0.7a
0.7±0.6a
Abdominal distension
2.2±0.7
1.2±0.6ab
0.6±0.5ab
2.2±0.7
1.8±0.4
1.1±0.7a
2.2±0.7
1.5±0.5a
0.9±0.5a
Table 3 Gastrointestinal symptom scores ( xˉ ± s)
Notes: ARD treatment group: patients were given 20-mg oral esomeprazole magnesium enteric-coated tablets once daily, 100-mg oral cele-
coxib capsules twice daily, and 15-mg oral methotrexate tablets once weekly. Moxibustion treatment group: patients were administered
ARD treatment plus ginger-partitioned moxibustion at Zusanli (ST 36). Combination treatment group: patients were administered ARD
treatment, moxibustion, and oral Sanhuangwuji powder (10 g per dose, three times a day). All treatments lasted 8 weeks. ARD: anti-rheu-
matic drug. aP < 0.05 for intragroup comparison; bP < 0.05 for intergroup comparison.
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and soluble IL-2 receptor levels, improved metatarsal
joint swelling, and enhanced methotrexate treatment
efficacy in RA rats. Ouyang et al 20 found that elec-
troacupuncture on patients with RA could increase
TNF-α and VEGF levels in the peripheral blood and
joint synovia, which was clinically effective for RA
treatment. Acupuncture can also relieve a wide range
of pain syndromes, such as neck disorders, ten-
sion-type headaches, peripheral joint osteoarthritis,
RA, shoulder pain, and lower back pain.
Sanhuangwuji power consists of Huangqin (Radix Scu-
tellariae Baicalensis), Huanglian (Rhizoma Coptidis),
Huangbai (Cortex Phellodendri Amurensis), and Dilong
(Pheretima Aspergillum), with Haipiaoxiao (Endoconcha
Sepiellae), and Baiji (Rhizoma Bletillae Striatae). Baica-
lein, a compound extracted from Huangqin (Radix Scu-
tellariae Baicalensis), can inhibit the production of in-
flammatory cytokines by suppressing the activation of
the transcription factor, nuclear factor-kappa light-chain
enhancer of activated B cells, and the phosphorylation
of nuclear factor of kappa light-polypeptide gene en-
hancer in B-cell inhibitors, alpha. Baicalein can also ar-
rest the degranulation of mast cells.21 Berberine, a com-
mon compound found in Huanglian (Rhizoma Copti-
dis) and Huangbai (Cortex Phellodendri Amurensis), can
improve synovitis and inhibit the specific immune re-
sponse in mice with collagen-induced arthritis, by sup-
pressing the secretion of interferon-γ, IL-17, IL-2, and
IL-10.22 Dilong (Pheretima Aspergillum) significantly in-
hibits histamine-induced mouse hind paw swelling, ros-
in-induced inflammatory granuloma formation, and
yeast-induced fever.23 In our previous study, Sanhuan-
gyilong decoction which mainly included Huangqin
(Radix Scutellariae Baicalensis), Huanglian (Rhizoma
Coptidis), Huangbai (Cortex Phellodendri Amurensis),
Dilong (Pheretima Aspergillum), and Fuling (Poria co-
cos), could improve synovitis and immunity, and was
effective significantly faster than NSAIDs.24 Haipiaoxi-
ao (Endoconcha Sepiellae), and Baiji (Rhizoma Bletillae
Striatae) have potent anti-acid, hemostatic, and analge-
sic effects, and are often used for the treatment of pep-
tic ulcer.25,26
In conclusion, oral Sanhuangwuji powder, in combina-
tion with ginger-partitioned stimulation at the Zusanli
(ST 36) acupoint, a proton pump inhibitor, a COX-2
inhibitor, and a disease-modifying ARD, is an effective
treatment for patients with RA complicated by peptic
ulcer.
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